Literature DB >> 745013

Absence of "cheese effect" during deprenyl therapy: some recent studies.

M Sandler, V Glover, A Ashford, G M Stern.   

Abstract

Although the selective monoamine oxidase (MAO) B inhibitor, (-)deprenyl, has been shown to be free from the "cheese effect" in man after tyramine challenge, the reason for this is far from clear: it may well be independent of the selective inhibitory action of the drug, for during chronic administration there is some evidence to suggest that both A and B forms of the enzyme are equally inhibited. By-passing the putative MAO A gut barrier in the pig (chosen because it possesses MAO B alone in all other tissues) by intravenous tyramine administration into the deprenyl-pretreated animal failed to provoke a pressor response, despite substantial MAO inhibition. Conversely, clorgyline (MAO A inhibitor) pretreatment, which resulted in minimal MAO inhibition, produced a profound hypertensive response, resembling that observed with the non-MAO-inhibiting drug, isoniazid. The most parsimonious explanation for these findings may be that two separate but closely associated pharmacological effects are normally found with "orthodox" MAO inhibitors, enzyme inhibition proper and facilitation of noradrenaline release from its binding sites during tyramine challenge.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 745013     DOI: 10.1007/bf01246957

Source DB:  PubMed          Journal:  J Neural Transm            Impact factor:   3.575


  19 in total

1.  The effect of urinary pH and flow rate on monoamine output.

Authors:  G P Reynolds; P M Ceasar; C R Ruthven; M Sandler
Journal:  Clin Chim Acta       Date:  1978-03-01       Impact factor: 3.786

2.  Beta-phenylethylamine: a specific substrate for type B monoamine oxidase of brain.

Authors:  H Y Yang; N H Neff
Journal:  J Pharmacol Exp Ther       Date:  1973-11       Impact factor: 4.030

3.  Multiple forms of monoamine oxidase in intact mitochondria as characterized by selective inhibitors and thermal stability: a comparison of eight mammalian species.

Authors:  R F Squires
Journal:  Adv Biochem Psychopharmacol       Date:  1972

4.  Dopamine is a monoamine oxidase B substrate in man.

Authors:  V Glover; M Sandler; F Owen; G J Riley
Journal:  Nature       Date:  1977-01-06       Impact factor: 49.962

5.  Isoniazid and reaction to cheese.

Authors:  C K Smith; D T Durack
Journal:  Ann Intern Med       Date:  1978-04       Impact factor: 25.391

6.  Interactions between sympathomimetic amines and a new monoamine oxidase inhibitor.

Authors:  M H Lader; G Sakalis; M Tansella
Journal:  Psychopharmacologia       Date:  1970-08-19

7.  Deprenil: loss of selectivity for inhibition of B-type MAO after repeated treatment.

Authors:  P C Waldmeier; A E Felner
Journal:  Biochem Pharmacol       Date:  1978-03-01       Impact factor: 5.858

8.  Clinical trial of a new type promptly acting psychoenergetic agent (phenyl-isopropyl-methylpropinyl-HCl, "E-250").

Authors:  E Varga; L Tringer
Journal:  Acta Med Acad Sci Hung       Date:  1967

9.  Implications of combined treatment with 'Madopar' and L-deprenil in Parkinson's disease. A long-term study.

Authors:  W Birkmayer; P Riederer; L Ambrozi; M B Youdim
Journal:  Lancet       Date:  1977-02-26       Impact factor: 79.321

10.  Deprenyl in Parkinson's disease.

Authors:  A J Lees; K M Shaw; L J Kohout; G M Stern; J D Elsworth; M Sandler; M B Youdim
Journal:  Lancet       Date:  1977-10-15       Impact factor: 79.321

View more
  10 in total

1.  Pressor response to oral tyramine and monoamine oxidase inhibition during treatment with ralfinamide (NW-1029).

Authors:  Andrea F D Di Stefano; Milko Massimiliano Radicioni; Antonio Rusca
Journal:  Neurotox Res       Date:  2012-08-08       Impact factor: 3.911

Review 2.  The significance of selegiline/(-)-deprenyl after 50 years in research and therapy (1965-2015).

Authors:  I Miklya
Journal:  Mol Psychiatry       Date:  2016-08-02       Impact factor: 15.992

3.  Pressor response to oral tyramine during co-administration with safinamide in healthy volunteers.

Authors:  Andrea Francesco Daniele Di Stefano; Antonio Rusca
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2011-08-19       Impact factor: 3.000

4.  In vitro formation of selegiline-N-oxide as a metabolite of selegiline in human, hamster, mouse, rat, guinea-pig, rabbit and dog.

Authors:  Ferenc Lévai; Erzsébet Fejér; Gábor Szeleczky; Anna Szabó; Tünde Eros-Takácsy; Félix Hajdu; Gyula Szebeni; István Szatmári; István Hermecz
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2004 Jul-Sep       Impact factor: 2.441

Review 5.  The pharmacology of Parkinson's disease: basic aspects and recent advances.

Authors:  M Da Prada; H H Keller; L Pieri; R Kettler; W E Haefely
Journal:  Experientia       Date:  1984-11-15

6.  Tyramine infusions and selective monoamine oxidase inhibitor treatment. I. Changes in pressor sensitivity.

Authors:  D Pickar; R M Cohen; D C Jimerson; D L Murphy
Journal:  Psychopharmacology (Berl)       Date:  1981       Impact factor: 4.530

7.  Modification of blood pressure and nictitating membrane response to sympathetic amines by selective monoamine oxidase inhibitors, types A and B, in the cat.

Authors:  J P Finberg; M B Youdim
Journal:  Br J Pharmacol       Date:  1985-06       Impact factor: 8.739

8.  Deprenyl in the management of response fluctuations in patients with Parkinson's disease on levodopa.

Authors:  M Schachter; C D Marsden; J D Parkes; P Jenner; B Testa
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-11       Impact factor: 10.154

9.  Adjunctive therapy in Parkinson's disease: the role of rasagiline.

Authors:  Kathryn D Gaines; Vanessa K Hinson
Journal:  Neuropsychiatr Dis Treat       Date:  2012-07-02       Impact factor: 2.570

Review 10.  The MPTP Story.

Authors:  J William Langston
Journal:  J Parkinsons Dis       Date:  2017       Impact factor: 5.568

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.